Humira (adalimumab) is a biological drug manufactured by Abbott Laboratories. Humira is a TNF Inhibitor that binds to the bodies’ TNF receptors preventing them from activating. Humira has been marketed by Abbott as an effective way of regulating the bodies inflammatory reaction to certain autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn's disease, chronic psoriasis, and juvenile idiopathic arthritis.
Humira is fast becoming the largest drug on the US market, with estimated sales in 2012 of around $10 billion.
Humira works by suppressing the bodies’ immune system. This has caused some patients to develop opportunistic infections, to reactivate latent infectious processes, to develop severe and never before experienced neurological problems, including demyelinating central nervous system disease and optic nerve damage and to the development of lymphoma and other cancers.
Goldberg & Goldberg has been on the cutting edge of the consolidated Humira litigation that is pending in the Circuit Court of Cook County, Illinois, In Re Humira Litigation, 2011 L 001224. Goldberg & Goldberg is the only Chicago area firm with primary responsibility for prosecuting the consolidated Humira cases. It is the position of the plaintiff’s that Abbott Laboratories failed to warn the users of Humira about the severe consequences of using Humira, even though they were more than aware of the dangers associated with using Humira.
We are currently interviewing clients from nationwide for inclusion in this litigation. Please feel free to contact us immeditately at 312-399-8660 to speak with an attorney about your case.